Axitinib
- Generic Name
- Axitinib
- Brand Names
- Inlyta, Axitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18N4OS
- CAS Number
- 319460-85-0
- Unique Ingredient Identifier
- C9LVQ0YUXG
- Background
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation V...
- Indication
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Thyroid cancer
- Associated Therapies
- First Line Chemotherapy
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT02133742
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 13
- Registration Number
- NCT02129647
- Locations
- 🇺🇸
NYU Langone Medical Center, New York, New York, United States
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT01999972
- Locations
- 🇺🇸
Investigational Drug Services IUHSCC, Indianapolis, Indiana, United States
🇺🇸IU Health University Hospital, Indianapolis, Indiana, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Tracon Pharmaceuticals Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT01806064
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇭🇺University of Debrecen Medical Center Institute of Oncology, Debrecen, Hungary
🇬🇧Sussex Cancer Center, Royal Sussex County Hospital, Brighton, East Sussex, United Kingdom
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
- Conditions
- Interventions
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT01798446
- Locations
- 🇰🇷
Seou National University Hospital, Seoul, Korea, Republic of
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Target Recruit Count
- 255
- Registration Number
- NCT01744249
- Locations
- 🇪🇸
Hospital Clínico San Carlos, Madrid, Spain
🇪🇸Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Complejo Hospitalario Univ A Coruña, A Coruña, Spain
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 65
- Registration Number
- NCT01693822
- Locations
- 🇬🇧
Royal Free Hospital, London, United Kingdom
🇬🇧Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
🇬🇧The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 3
- Registration Number
- NCT01649180
- Locations
- 🇺🇸
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, United States
🇺🇸Missouri Valley Cancer Consortium, Omaha, Nebraska, United States
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
- First Posted Date
- 2012-05-16
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- SFJ Pharma Ltd. II
- Target Recruit Count
- 724
- Registration Number
- NCT01599754
A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Bart Neyns
- Target Recruit Count
- 56
- Registration Number
- NCT01562197
- Locations
- 🇧🇪
UZ Brussel, Brussel, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.